Enanta Pharmaceuticals to Participate in Two Investor Conferences in November

Rhea-AI Summary

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that CEO Jay R. Luly, Ph.D., will participate in two upcoming investor conferences. The events include a Fireside Chat at the Piper Sandler 34th Annual Healthcare Conference on November 29 at 2:00 p.m. ET, and a session at the Evercore ISI 5th Annual HealthCONx Conference on November 30 at 3:30 p.m. ET. Live webcasts will be available on Enanta's website, with replays accessible for 30 days. Enanta focuses on developing small molecule drugs for viral infections, including RSV, COVID-19, and HBV.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in November:

• Piper Sandler 34^th Annual Healthcare Conference: Fireside Chat at 2:00 p.m. ET on November 29
• Evercore ISI 5^th Annual HealthCONx Conference: Fireside Chat at 3:30 p.m. ET on November 30

A live webcast of each event will be accessible by visiting under "Events & Presentations" in the investors section of Enanta’s at www.enanta.com. Replays of the webcasts will be available following the presentations and will be archived for approximately 30 days.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET^® (U.S.) and MAVIRET^® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005191/en/

Media and Investor Contact

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

What investor conferences will Enanta Pharmaceuticals attend in November 2023?

Enanta Pharmaceuticals will attend the Piper Sandler 34th Annual Healthcare Conference on November 29, 2023, and the Evercore ISI 5th Annual HealthCONx Conference on November 30, 2023.

What time will the conferences featuring Enanta Pharmaceuticals take place?

The Piper Sandler conference will feature a Fireside Chat at 2:00 p.m. ET, and the Evercore ISI conference will have a session at 3:30 p.m. ET.

Where can I watch the Enanta Pharmaceuticals conference webcasts?

The webcasts can be viewed on Enanta's website under the 'Events & Presentations' section in the investors section.

What diseases is Enanta Pharmaceuticals targeting with its drug development?

Enanta Pharmaceuticals is developing small molecule drugs for respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and hepatitis B virus (HBV).

What funding source supports Enanta Pharmaceuticals' research and development?

Enanta's research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under their collaboration with AbbVie.